Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07294534 | A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer | not yet recruiting | Phase 2 / Phase 3 | 817 | Shanghai Henlius BiotechINDUSTRY | 0 | Dec 19, 2025 | clinicaltrials |
| NCT07290166 | A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients.(Cinderella-Neo) | not yet recruiting | Phase 2 | 42 | Fudan University |
| 0 |
| Dec 18, 2025 |
| clinicaltrials |
| NCT07292142 | FMT in Triple Negative Breast Cancer Guided by ctDNA(FRIDA) | not yet recruiting | Phase 1 / Phase 2 | 125 | Jewish General HospitalOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07292207 | Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast Cancer(ARCHE) | not yet recruiting | Phase 2 | 30 | Nagoya City UniversityOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05128734 | Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) | not yet recruiting | Phase 2 | 40 | AHS Cancer Control AlbertaOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT07271992 | TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer(TREND-02) | not yet recruiting | Phase 2 | 30 | First Hospital of China Medical UniversityOTHER | 0 | Dec 9, 2025 | clinicaltrials |
| NCT07260058 | Immune Cell Therapy for Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 48 | Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.INDUSTRY | 0 | Dec 2, 2025 | clinicaltrials |
| NCT07255612 | Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer) | not yet recruiting | Phase 2 | 29 | Sun Yat-sen UniversityOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07246317 | Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer | not yet recruiting | Phase 2 | 188 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT07254858 | Combined Chemo-immunotherapy Plus SBRT in Neoadjuvant Treatment for Luminal Subtype Breast Cancer(CISN-L) | not yet recruiting | Phase 2 | 302 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT07243418 | Hetrombopag for the Prevention of ADC-Induced Thrombocytopenia in Breast Cancer: An Exploratory, Dual-Cohort, Phase 2 Study | not yet recruiting | Phase 2 | 72 | Fujian Cancer HospitalOTHER_GOV | 0 | Nov 21, 2025 | clinicaltrials |
| NCT07235618 | A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer | not yet recruiting | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT07178938 | Platform Trial Assessing Uptake, Safety and Efficacy of Theranostic Agents in Solid Tumors With Active Brain Metastases(THERANOVA) | not yet recruiting | Phase 2 | 10 | MedSIROTHER | 0 | Nov 14, 2025 | clinicaltrials |
| NCT07197697 | A Phase II Exploratory Study of Iparomlimab and Tuvonralimab Combined With Chemotherapy in Neoadjuvant Treatment of HR+/HER2- Breast Cancer Patients | not yet recruiting | Phase 2 | 30 | Anhui Provincial Cancer HospitalOTHER | 0 | Sep 29, 2025 | clinicaltrials |
| NCT07189884 | Pyrotinib Maleate Tablets in Combination With Dalpiciclib Isethionate Tablets and Standard Endocrine Therapy | not yet recruiting | Phase 1 / Phase 2 | 33 | The First Affiliated Hospital of Xiamen UniversityOTHER | 0 | Sep 24, 2025 | clinicaltrials |
| NCT07179939 | Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study | not yet recruiting | Phase 2 | 288 | Fudan UniversityOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07177950 | A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases | not yet recruiting | Phase 1 / Phase 2 | 51 | Peking University Cancer Hospital & InstituteOTHER | 0 | Sep 17, 2025 | clinicaltrials |
| NCT07173556 | A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 96 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 15, 2025 | clinicaltrials |
| NCT05806385 | Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers(LOGIC) | not yet recruiting | Phase 1 / Phase 2 | 36 | Texas Tech University Health Sciences CenterOTHER | 0 | Sep 9, 2025 | clinicaltrials |
| NCT07161791 | Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 12 | Harbin Medical UniversityOTHER | 0 | Sep 9, 2025 | clinicaltrials |
| NCT07040644 | A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC | not yet recruiting | Phase 2 | 150 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07153965 | Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer | not yet recruiting | Phase 2 | 47 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07129187 | SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response | not yet recruiting | Phase 2 | 30 | Chuan WangOTHER | 0 | Aug 26, 2025 | clinicaltrials |
| NCT07139470 | Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 59 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT07136974 | Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer. | not yet recruiting | Phase 2 | 280 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 22, 2025 | clinicaltrials |
| NCT07132242 | SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer | not yet recruiting | Phase 2 | 84 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Aug 20, 2025 | clinicaltrials |
| NCT07107217 | Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer(Camella) | not yet recruiting | Phase 2 | 40 | Blokhin's Russian Cancer Research CenterOTHER | 0 | Aug 17, 2025 | clinicaltrials |
| NCT07125950 | SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer | not yet recruiting | Phase 2 | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 15, 2025 | clinicaltrials |
| NCT07116824 | HB1801 Combined Treatment of HER2-positive Breast Cancer | not yet recruiting | Phase 2 | 80 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Aug 12, 2025 | clinicaltrials |
| NCT06973525 | This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy.(HER2-DM-NACT) | not yet recruiting | Phase 2 | 30 | Hebei Medical University Fourth HospitalOTHER | 0 | Aug 5, 2025 | clinicaltrials |
| NCT07007780 | Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC | not yet recruiting | Phase 2 | 35 | Xijing HospitalOTHER | 0 | Jul 29, 2025 | clinicaltrials |
| NCT07083505 | A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer | not yet recruiting | Phase 2 | 60 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Jul 24, 2025 | clinicaltrials |
| NCT07067307 | Melatonin in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy | not yet recruiting | Phase 1 / Phase 2 | 80 | Mansoura UniversityOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT07047443 | SHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 Expression | not yet recruiting | Phase 2 | 18 | Anhui Provincial Cancer HospitalOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT07047755 | Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC | not yet recruiting | Phase 2 | 48 | Henan Cancer HospitalOTHER_GOV | 0 | Jul 2, 2025 | clinicaltrials |
| NCT07041437 | Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer | not yet recruiting | Phase 2 | 48 | Fudan UniversityOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT07019337 | Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer | not yet recruiting | Phase 2 | 100 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jun 13, 2025 | clinicaltrials |
| NCT07011823 | Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC(KEY-MELT) | not yet recruiting | Phase 2 | 20 | Gangnam Severance HospitalOTHER | 0 | Jun 10, 2025 | clinicaltrials |
| NCT07005583 | Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer | not yet recruiting | Phase 2 | 46 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06977542 | Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer | not yet recruiting | Phase 2 | 53 | Fudan UniversityOTHER | 0 | May 18, 2025 | clinicaltrials |
| NCT06975462 | A Phase II Study of SHR-A1811 Combined With Radiotherapy in HER2-positive and HER2-low Breast Cancer Brain Metastases | not yet recruiting | Phase 2 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | May 16, 2025 | clinicaltrials |
| NCT06975475 | SHR-A1811 and THPy in First or Second Line for HER2 Positive Advanced Breast Cancer Brain Metastases | not yet recruiting | Phase 2 | 60 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | May 16, 2025 | clinicaltrials |
| NCT06976021 | Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy(INTROSPECTION) | not yet recruiting | Phase 2 | 60 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 0 | May 16, 2025 | clinicaltrials |
| NCT06632405 | A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC | not yet recruiting | Phase 2 | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Mar 26, 2025 | clinicaltrials |
| NCT06788197 | A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer Patients | not yet recruiting | Phase 1 / Phase 2 | 52 | Henan Cancer HospitalOTHER_GOV | 0 | Mar 26, 2025 | clinicaltrials |
| NCT06775236 | Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 410 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Mar 19, 2025 | clinicaltrials |
| NCT06849492 | HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer(SHIFT-001) | not yet recruiting | Phase 2 | 120 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06842472 | PD-L1 Inhibitor + RT ± Ursodeoxycholic Acid in Recurrent/Metastatic HER2-Neg Breast Cancer | not yet recruiting | Phase 2 | 70 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Feb 24, 2025 | clinicaltrials |
| NCT05821686 | Efficacy of Interleukin-2 in Triple Negative Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 10 | Nova Scotia Health AuthorityOTHER | 0 | Feb 12, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 19, 2025source: clinicaltrials